MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer. Andolfi C, Bartolini C, Morales E, Gundogdu B, et al. Endocrinology 2024;165:bqae114.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Andolfi C, Bartolini C, Morales E, Gundogdu B, et al. MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer. Endocrinology 2024;165:bqae114.
PMID: 39253786